Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

Core Insights - Abeona Therapeutics has completed its first commercial patient treatment of ZEVASKYN in December 2025, with plans to build momentum for its launch in the first quarter of 2026 [1][7] - The company reported total revenue of $5.8 million for the year ended December 31, 2025, which includes $3.4 million in license and other revenues and $2.4 million in net product revenue [3][9] - Abeona's net income for 2025 was $71.2 million, a significant turnaround from a net loss of $63.7 million in 2024 [9][14] Financial Performance - Total revenue for 2025 was $5.8 million, consisting of $2.4 million in net product revenue and $3.4 million in license and other revenues [3][14] - Cost of sales for 2025 was $1.5 million, primarily due to the first commercial treatment of ZEVASKYN and production costs from an August batch that faced technical challenges [5][14] - Research and development (R&D) spending decreased to $26.8 million in 2025 from $34.4 million in 2024, attributed to the FDA approval of ZEVASKYN [6][14] - Selling, general and administrative (SG&A) expenses rose to $65.0 million in 2025, an increase of $35.1 million over 2024, reflecting the company's commercial transition post-FDA approval [7][14] Operational Updates - The first ZEVASKYN treatment was completed in December 2025, with ongoing efforts to streamline the treatment process and expand patient access [1][4][7] - Abeona has activated The University of Texas Medical Branch (UTMB) as the fourth Qualified Treatment Center (QTC) for ZEVASKYN, enhancing patient access in Texas and the Gulf Coast region [7] - The company anticipates that positive patient experiences will drive sustained demand for ZEVASKYN within the recessive dystrophic epidermolysis bullosa (RDEB) community [7] Cash Position - As of December 31, 2025, Abeona reported cash, cash equivalents, and short-term investments totaling $191.4 million [1][9]